Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
Advances in acute myeloid leukemia
LF Newell, RJ Cook - Bmj, 2021 - bmj.com
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …
historically high mortality rates. The standard of care treatment remained unchanged for …
Acute myeloid leukemia: current progress and future directions
H Kantarjian, T Kadia, C DiNardo, N Daver… - Blood cancer …, 2021 - nature.com
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
[HTML][HTML] Azacitidine and venetoclax in previously untreated acute myeloid leukemia
CD DiNardo, BA Jonas, V Pullarkat… - … England Journal of …, 2020 - Mass Medical Soc
Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis,
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
AH Wei, P Montesinos, V Ivanov… - Blood, The Journal …, 2020 - ashpublications.org
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia
CD DiNardo, CA Lachowiez, K Takahashi… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-
AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients …
AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients …
[HTML][HTML] Targeting FTO suppresses cancer stem cell maintenance and immune evasion
Fat mass and obesity-associated protein (FTO), an RNA N 6-methyladenosine (m 6 A)
demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the …
demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
CD DiNardo, IS Tiong, A Quaglieri… - Blood, The Journal …, 2020 - ashpublications.org
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …